Haijun Tong

Title: Haijun Tong: Innovator in Tumor Inhibition

Introduction

Haijun Tong is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of tumor-inhibiting therapies. With a total of 2 patents, his work focuses on innovative approaches to cancer treatment.

Latest Patents

One of Haijun Tong's latest patents is titled "Subject-Specific Tumor Inhibiting Cells and the Use Thereof." This patent discloses a pharmaceutical composition that comprises tumor inhibiting cells (TICs) and a method for producing these cells. The TICs can be derived from immune cells, including T cells and NK cells, which are modified to have inactivated Cbl-b gene alleles. Importantly, these Cbl-bTICs are free from exogenous deoxyribonucleic acids. The immune cells can be isolated using a portable cell isolation and modification device. This innovative approach aims to provide subject-specific tumor treatment, offering new hope for patients with tumorous conditions.

Career Highlights

Throughout his career, Haijun Tong has worked with various companies, including Ezy Biotech LLC and Adaerata, Limited Partnership. His expertise in biotechnology and cancer research has positioned him as a key figure in the development of advanced therapeutic solutions.

Collaborations

Haijun Tong has collaborated with notable professionals in his field, including Hua Gu and Gang G Xu. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Haijun Tong's innovative work in tumor inhibition exemplifies the potential of biotechnology to transform cancer treatment. His contributions through patents and collaborations highlight the importance of research in developing effective therapies for patients.